Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors.
Thirty-eight disulfides containing N-arylacetamide were designed and synthesized in an effort to develop novel urease inhibitors. Biological evaluation revealed that some of the synthetic compounds exhibited strong inhibitory potency against both cell-free urease and urease in intact cell with low cytotoxicity to mammalian cells even at concentration up to 250 μM. Of note, 2,2'-dithiobis(N-(2-fluorophenyl)acetamide) (d7), 2,2'-dithiobis(N-(3,5-difluorophenyl)acetamide) (d24), and 2,2'-dithiobis(N-(3-fluorophenyl)acetamide) (d8) were here identified as the most active inhibitors with IC50 of 0.074, 0.44, and 0.81 μM, showing 32- to 355-fold higher potency than the positive control acetohydroxamic acid. These disulfides were confirmed to bind urease without covalent modification of the cysteine residue and to inhibit urease reversibly with a mixed inhibition mechanism. They also showed very good anti-Helicobacter pylori activities with d8 showing a comparable potency to the clinical used drug amoxicillin. The impressive in vitro biological profile indicated their immense potential as therapeutic agents to tackle H. pylori caused infections.
['Liu|Mei-Ling|ML|', 'Li|Wei-Yi|WY|', 'Fang|Hai-Lian|HL|', 'Ye|Ya-Xi|YX|', 'Li|Su-Ya|SY|', 'Song|Wan-Qing|WQ|', 'Xiao|Zhu-Ping|ZP|http://orcid.org/0000-0001-6345-7436', 'Ouyang|Hui|H|', 'Zhu|Hai-Liang|HL|']
Dithiobisacetamide Helicobacter pylori cytotoxicity. reversible urease inhibitor